Every letter we have printed

A fair hit. We can describe the pharmacology accurately and still be writing at a distance from how the decision lands, and the paragraph you object to does both. The reframing is offered as a corrective to a stigma, not as a claim that the stigma is imaginary.

Treat the nominal figure as an upper bound and say so out loud when reasoning about a dose. It is an unsatisfying answer and it is the honest one. We have argued in Analytics that content should be a standard reported field, and we will keep naming the services that report it and those that do not.

Nor do we, and the file should have been clearer. The four-week interval is a floor below which the previous rung is still accumulating, not a threshold below which escalation is unsafe. Plenty of people tolerate faster ascent. Our objection is to the inverse inference — that because you did, everybody should — and to the absence of a trial that would let anyone say which is which in advance.

Correct on the pressure cost, and that belongs in the method section. The trade-off is real, which is why many laboratories use core-shell superficially porous particles as a compromise: they are substantially cheaper than sub-two-micron packings, deliver most of the efficiency gain at a lower pressure, and the efficiency-cost-pressure triangle is the actual business decision people make. We should have named it.

That is an important structural point and it changes where the fix has to happen. If the laboratory report travels intact instead of being transcribed into a house certificate, the method travels with it. Four of the twenty companies we track already attach the original report, and on this argument they are doing the single most useful thing available.

That is an important structural point and it changes where the fix has to happen. If the laboratory report travels intact instead of being transcribed into a house certificate, the method travels with it. Four of the twenty companies we track already attach the original report, and on this argument they are doing the single most useful thing available.

A fair objection and we have adjusted the wording. Our intention was to locate the absence with the people who could have funded the trial rather than with the clinicians managing without it, and on rereading the original paragraph did not achieve that.

Almost certainly from cross-trial comparison of weight-loss percentages, which is not an equivalence basis. There is no head-to-head dose-titration study permitting conversion between these agents, and STEP 8 — the only head-to-head weight trial we know of — compared two agents at their own licensed doses rather than establishing equivalence between them.

Both, we think, and deliberately. There is no pharmacological rationale, because there is no withdrawal syndrome and a week-long half-life produces its own decline. There is a behavioural rationale, which is different in kind and untested. Our objection is to tapers advocated in pharmacological language, not to the practice.

It is entirely predictable from the label and the pharmacokinetics, and the failure to communicate it during the shortage period was systemic rather than individual. We are sorry it reached you this way and we are glad it reached you.

Deliberate, and worth explaining. A tenth of a percentage point on a figure with a confidence interval several points wide implies a precision the data does not have. We give the exact figure in the tables and round in prose, which is a convention we should have stated rather than left to be noticed.

That binary is the specific failure this file was written against. Stepping back a rung and re-approaching later is permitted in every pivotal protocol in this class and is absent from most conversations about it. We cannot comment on your care, but the framing you were given does not reflect either the trial conduct or the labelling.

It is, and it is a compromise with how readers search. The tag exists because that is the word people use; the glossary exists because it is the wrong one. We would rather be findable and then precise than precise and unread.

Deliberate, and worth explaining. A tenth of a percentage point on a figure with a confidence interval several points wide implies a precision the data does not have. We give the exact figure in the tables and round in prose, which is a convention we should have stated rather than left to be noticed.

That binary is the specific failure this file was written against. Stepping back a rung and re-approaching later is permitted in every pivotal protocol in this class and is absent from most conversations about it. We cannot comment on your care, but the framing you were given does not reflect either the trial conduct or the labelling.

It belongs, labelled. The table is a map of what is recommended and on what basis, not a list of endorsements, and excluding widely used low-risk measures because their evidence is transferred would make the map less useful rather than more honest. We have made the column heading clearer.

The folk model that suffering indexes efficacy is widespread and the published analyses do not support it. It is also actively harmful when it drives escalation, which is why we gave it a line in the closing section rather than burying it in the tables.

A real gap and we will address it properly rather than in a reply. The short version is that it is a pharmacokinetic question — how much excess exposure, over what half-life — and a clinical one about symptom burden, and neither is answerable in the abstract. It also belongs in the titration file, which currently discusses omission and not excess.

A fair criticism of the reporting. Parcel 7 was submitted for purity determination on arrival and returned a figure within a percentage point of the supplier’s stated value, which is consistent with the solid-state argument and proves very little on its own, since we had no pre-shipment measurement on that vial. The design fault is ours: a shipment study without a paired baseline sample cannot answer the question we most wanted answered, and the next round will.

Correct, and the text has been amended. The discrimination is achievable under specialised conditions and is not available in any routine service this market uses, which is what we should have written rather than the stronger claim.

This is the hardest editorial question this department faces and we do not think you are wrong. Our position is that a practice this widespread is better described accurately, with its evidentiary status stated, than left to circulate in fragments. We accept that the distinction does work that a reader may not do.

The second. The published interquartile ranges around those means are wide, and outcomes like yours are well within them. The trials were not designed to explain why some people hold weight after cessation and others do not, and nothing measured at randomisation predicts it usefully. You are not an anomaly; you are part of a distribution nobody quotes.

Probably true in part, and it is the strongest argument against our proposal. Our answer is that gaming requires effort and leaves traces, which the present arrangement does not, and that a partially gamed record is more informative than no record. We would not claim more than that.

A fair hit. The tag under which this coverage sits predates the distinction we now draw, and we have added the distinction to the second paragraph and to the table. The department name will follow at the next reorganisation of the site.

Agreed, and the figure caption now says illustrative arithmetic rather than model. The point survives the simplification, which is that a small amount of selection produces a large apparent effect, but we should not have dressed a demonstration as an estimate.

That is the correct reading, and the unmeasurable part is the honest part. We would add only that vendor-published reports are not worthless — a vendor willing to commission testing at all is behaving better than one that will not — they are simply weaker in a specific way.

So do we, every time this department writes about the sector. The only answers we have are procedural: the disclosure, the standards desk edit, the consulting prohibition on the writer, and the practice of printing objections like yours unedited.

Both, we think, and deliberately. There is no pharmacological rationale, because there is no withdrawal syndrome and a week-long half-life produces its own decline. There is a behavioural rationale, which is different in kind and untested. Our objection is to tapers advocated in pharmacological language, not to the practice.

It is entirely predictable from the label and the pharmacokinetics, and the failure to communicate it during the shortage period was systemic rather than individual. We are sorry it reached you this way and we are glad it reached you.

A fair objection and we have adjusted the wording. Our intention was to locate the absence with the people who could have funded the trial rather than with the clinicians managing without it, and on rereading the original paragraph did not achieve that.

Almost certainly from cross-trial comparison of weight-loss percentages, which is not an equivalence basis. There is no head-to-head dose-titration study permitting conversion between these agents, and STEP 8 — the only head-to-head weight trial we know of — compared two agents at their own licensed doses rather than establishing equivalence between them.

It belongs, labelled. The table is a map of what is recommended and on what basis, not a list of endorsements, and excluding widely used low-risk measures because their evidence is transferred would make the map less useful rather than more honest. We have made the column heading clearer.

On the basis of the synthesis and analytical literature, where epimer formation during solid-phase assembly and during storage at extremes of pH is well characterised. What is missing is not evidence that it occurs but evidence about how much of it is present in any particular commercial vial, which is a different absence and the one we should have named.

It is, and it is a compromise with how readers search. The tag exists because that is the word people use; the glossary exists because it is the wrong one. We would rather be findable and then precise than precise and unread.

Deliberate, and worth explaining. A tenth of a percentage point on a figure with a confidence interval several points wide implies a precision the data does not have. We give the exact figure in the tables and round in prose, which is a convention we should have stated rather than left to be noticed.